It has been suggested that the CBR3-AS1/miR-509-3p/HDAC9 pathway is a valuable target for the therapy of NSCLC since it promotes tumor growth through the development and progression of NSCLC [30]. Here, CBR3 is linked to non-small cell lung carcinoma.